TALVEY® (talquetamab-tgvs) demonstrates highly durable, longer-term responses in patients with relapsed or refractory multiple myeloma
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: PR Newswire
24-month overall survival rate of 67 percent achieved with TALVEY® 0.8 mg/kg biweekly dosing in the Phase 1/2 MonumenTAL-1 studyMADRID, June 14, 2024 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) announced today that long-term data from the Phase 1/2 MonumenTAL-1 study showed that with 20 to 30 months of median follow-up, triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) who were treated with TALVEY® (talquetamab-tgvs) maintained high overall response rates (ORR) and durable responses, irrespective of whether they had received prior T-cell redirection therapy.1 These data, featured in a poster presentation at the 2024 European Hematology Association (EHA) Congress (Abstract #P915) demonstrate the efficacy and durability of TALVEY® when used before or after chimeric antigen receptor T-cell (CAR-T) therapy or bispecific antibody therapies in triple-class-exposed patients with RRMM.1 "Results from the MonumenTAL-1 study continue to show deeper response lev
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Global Intracranial Aneurysm Market Size To Worth USD 2.96 Billion By 2033 | CAGR Of 7.32% [Yahoo! Finance]Yahoo! Finance
- Face Cream Market size is set to grow by USD 12.20 billion from 2024-2028, Rising demand for natural and organic face creams boost the market, Technavio [Yahoo! Finance]Yahoo! Finance
- Statement by Coalition Representing More than 77,500 Individuals Harmed by Baby Powder Products [Yahoo! Finance]Yahoo! Finance
- J&J (JNJ) Seeks Expanded Use of Tremfya for Crohn's Disease [Yahoo! Finance]Yahoo! Finance
- Johnson & Johnson Completes Acquisition of Proteologix, Inc. [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 4/16/24 - Beat
JNJ
Sec Filings
- 6/6/24 - Form 4
- 6/6/24 - Form 4
- 5/28/24 - Form SD
- JNJ's page on the SEC website